<p>随着假期缩短的一周开始，美国主要股指下跌，科技股领跌，贵金属从近期高位回落。在如此波动的市场环境中，识别具有增长潜力的股票可能具有挑战性，但也充满回报。便士股票通常与较小或新兴公司相关，继续为愿意超越传统蓝筹股选择的投资者提供引人注目的机会。当这些股票背靠强大的财务健康和稳固的基本面时，能够提供显著的增长潜力。</p>
<h3>美国前 10 大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.68</td>
<td>$617.2M</td>
<td>✅ 3 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.88</td>
<td>$679.93M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8371</td>
<td>$145.28M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.30</td>
<td>$555.27M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.14</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.29</td>
<td>$563.4M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Nephros (NEPH)</td>
<td>$4.87</td>
<td>$51.75M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$1.00</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.08</td>
<td>$92.44M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国便士股票筛选器中的 339 只股票的完整列表。</p>
<p>让我们从我们的专业筛选器中发现一些宝藏。</p>
<h2>Vuzix (VUZI)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Vuzix Corporation 设计、制造和销售全球范围内的 AI 驱动智能眼镜、波导和增强现实技术，市值为 2.6922 亿美元。</p>
<p><strong>运营：</strong> 该公司的收入主要来自其视频眼镜产品部门，贡献了 531 万美元。</p>
<p><strong>市值：</strong> 2.6922 亿美元</p>
<p>Vuzix Corporation 市值为 2.6922 亿美元，积极寻求战略联盟并扩大客户基础，以增强其在增强现实领域的地位。与 Collins Aerospace 在国防应用方面的近期合作以及与 BUNDLAR 的合作突显了潜在的增长途径。尽管从视频眼镜产品中产生了 531 万美元的收入，Vuzix 仍处于亏损状态，过去五年亏损不断增加，但相对于负债保持强劲的现金状况。公司的管理层经验丰富，且没有债务，尽管股价波动性较大，但预计年收入增长率为 75.45%。</p>
<ul>
<li>点击这里阅读我们的资产负债表健康报告，深入了解 Vuzix 的表现。</li>
<li>通过查看我们的增长报告，了解 Vuzix 的盈利前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/640652d4-24b2-40b7-a422-0318e30959b3/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/640652d4-24b2-40b7-a422-0318e30959b3/chart/financial-position-analysis"/></p>
<p>截至 2025 年 12 月的 VUZI 财务状况分析</p>
<h2>Aclaris Therapeutics (ACRS)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Aclaris Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发针对美国免疫炎症疾病的新型药物候选者，市值为 3.2612 亿美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其治疗部门，产生了 1376 万美元，以及合同研究服务，贡献了 1637 万美元。</p>
<p><strong>市值：</strong> 3.2612 亿美元</p>
<p>Aclaris Therapeutics 市值为 3.2612 亿美元，正在应对波动的便士股票市场，同时专注于免疫炎症治疗。尽管处于亏损状态且亏损不断增加，但公司无债务，保持强劲的现金状况，短期资产为 1.006 亿美元，超过负债。最近被纳入纳斯达克生物技术指数可能会提高投资者的关注度。收入从去年同期的 435 万美元下降至 2025 年第三季度的 330 万美元，但预计年收入增长率为 22.29%，在股价波动性较大和管理团队经验不足的情况下提供潜在的上行空间。</p>
<ul>
<li>点击探索我们在 Aclaris Therapeutics 财务健康报告中的详细发现。</li>
<li>通过查看我们的增长报告，获取 Aclaris Therapeutics 的未来方向的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b035627f-e16a-442f-99a6-969783c043a7/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b035627f-e16a-442f-99a6-969783c043a7/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 12 月的 ACRS 债务与股本历史及分析</p>
<h2>Prelude Therapeutics (PRLD)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家临床阶段的精准肿瘤学公司，致力于为服务不足的患者发现和开发新型癌症药物，市值为 2.4225 亿美元。</p>
<p><strong>运营：</strong> Prelude Therapeutics 从其生物技术（初创公司）部门产生收入，总计 1050 万美元。</p>
<p><strong>市值：</strong> 2.4225 亿美元</p>
<p>Prelude Therapeutics 市值为 2.4225 亿美元，专注于精准肿瘤学，正在应对便士股票市场。尽管处于亏损状态且股本回报率为负，但公司无债务，保持足够的短期资产以覆盖负债。公司最近通过私募融资筹集了 2500 万美元，并申请了 912.5 万美元的货架注册，表明其努力在当前的 7 个月现金流之外增强现金储备。最近在主要会议上展示的临床前数据突显了其 JAK2V617F 抑制剂和 mCALR 靶向疗法的有希望进展，尽管股价波动性较大，但可能会增强投资者的兴趣。</p>
<ul>
<li>通过我们的综合资产负债表健康报告，深入了解 Prelude Therapeutics 的复杂性。</li>
<li>查看我们的增长表现报告，以获取对 Prelude Therapeutics 未来的洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 12 月 PRLD 债务与股本历史及分析</p>
<h2>将想法转化为行动</h2>
<ul>
<li>点击这里仔细查看我们 339 家美国便士股票公司的名单。</li>
<li>考虑其他策略？最新的 GPU 需要一种叫做铽的稀土金属，全球只有 38 家公司在探索或生产它。免费获取名单。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>移动基础设施用于国防和灾难应对</p>
<p>下一波机器人技术不是类人型的，而是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

VUZI

PRLD

<p>随着美国股指下跌，低价股为投资者提供了增长机会。值得注意的股票包括 Vuzix Corporation（市值 2.6922 亿美元），专注于人工智能驱动的智能眼镜，以及 Aclaris Therapeutics（市值 3.2612 亿美元），这是一家开发免疫炎症疾病治疗方案的生物制药公司。Prelude Therapeutics（市值 2.4225 亿美元）专注于精准肿瘤学。尽管这些公司尚未盈利，但它们保持着强劲的现金储备，并正在探索战略合作伙伴关系以增强增长潜力。投资者被鼓励在市场波动中考虑这些新兴股票</p>

<p>As the holiday-shortened week begins, major U.S. stock indexes have dipped, with technology shares leading the decline and precious metals retreating from recent highs. In such a fluctuating market landscape, identifying stocks with potential for growth can be challenging but rewarding. Penny stocks, often associated with smaller or emerging companies, continue to offer intriguing opportunities for investors willing to explore beyond traditional blue-chip options. These stocks can provide significant growth potential when backed by strong financial health and solid fundamentals.</p>
<div class="lb-trans"><p>随着假期缩短的一周开始，美国主要股指下跌，科技股领跌，贵金属从近期高位回落。在如此波动的市场环境中，识别具有增长潜力的股票可能具有挑战性，但也充满回报。便士股票通常与较小或新兴公司相关，继续为愿意超越传统蓝筹股选择的投资者提供引人注目的机会。当这些股票背靠强大的财务健康和稳固的基本面时，能够提供显著的增长潜力。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国前 10 大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.68</td>
<td>$617.2M</td>
<td>✅ 3 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.88</td>
<td>$679.93M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8371</td>
<td>$145.28M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.30</td>
<td>$555.27M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.14</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.29</td>
<td>$563.4M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Nephros (NEPH)</td>
<td>$4.87</td>
<td>$51.75M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$1.00</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.08</td>
<td>$92.44M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.68</td>
<td>$617.2M</td>
<td>✅ 3 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.88</td>
<td>$679.93M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8371</td>
<td>$145.28M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.30</td>
<td>$555.27M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.14</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.29</td>
<td>$563.4M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Nephros (NEPH)</td>
<td>$4.87</td>
<td>$51.75M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$1.00</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.08</td>
<td>$92.44M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 339 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国便士股票筛选器中的 339 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>让我们从我们的专业筛选器中发现一些宝藏。</p>
</div><h2>Vuzix (VUZI)</h2>
<div class="lb-trans"><h2>Vuzix (VUZI)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Vuzix Corporation designs, manufactures, and markets AI-powered smart glasses, waveguides, and augmented reality technologies globally with a market cap of $269.22 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Vuzix Corporation 设计、制造和销售全球范围内的 AI 驱动智能眼镜、波导和增强现实技术，市值为 2.6922 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates its revenue primarily from its Video Eyewear Products segment, which accounted for $5.31 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入主要来自其视频眼镜产品部门，贡献了 531 万美元。</p>
</div><p><strong>Market Cap:</strong> $269.22M</p>
<div class="lb-trans"><p><strong>市值：</strong> 2.6922 亿美元</p>
</div><p>Vuzix Corporation, with a market cap of US$269.22 million, has been actively pursuing strategic alliances and expanding its client base to bolster its position in the augmented reality sector. Recent collaborations with Collins Aerospace for defense applications and partnerships like BUNDLAR highlight potential growth avenues. Despite generating US$5.31 million from Video Eyewear Products, Vuzix remains unprofitable with increasing losses over five years but maintains a strong cash position relative to liabilities. The company's management is experienced, and it has no debt, though high share price volatility persists alongside significant revenue growth forecasts of 75.45% annually.</p>
<div class="lb-trans"><p>Vuzix Corporation 市值为 2.6922 亿美元，积极寻求战略联盟并扩大客户基础，以增强其在增强现实领域的地位。与 Collins Aerospace 在国防应用方面的近期合作以及与 BUNDLAR 的合作突显了潜在的增长途径。尽管从视频眼镜产品中产生了 531 万美元的收入，Vuzix 仍处于亏损状态，过去五年亏损不断增加，但相对于负债保持强劲的现金状况。公司的管理层经验丰富，且没有债务，尽管股价波动性较大，但预计年收入增长率为 75.45%。</p>
</div><ul>
<li>Get an in-depth perspective on Vuzix's performance by reading our balance sheet health report here.</li>
<li>Understand Vuzix's earnings outlook by examining our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里阅读我们的资产负债表健康报告，深入了解 Vuzix 的表现。</li>
<li>通过查看我们的增长报告，了解 Vuzix 的盈利前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/640652d4-24b2-40b7-a422-0318e30959b3/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/640652d4-24b2-40b7-a422-0318e30959b3/chart/financial-position-analysis"/></p>
<p>VUZI Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 VUZI 财务状况分析</p>
</div><h2>Aclaris Therapeutics (ACRS)</h2>
<div class="lb-trans"><h2>Aclaris Therapeutics (ACRS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune-inflammatory diseases in the United States, with a market cap of $326.12 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aclaris Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发针对美国免疫炎症疾病的新型药物候选者，市值为 3.2612 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Therapeutics segment, generating $13.76 million, and Contract Research services, contributing $16.37 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其治疗部门，产生了 1376 万美元，以及合同研究服务，贡献了 1637 万美元。</p>
</div><p><strong>Market Cap:</strong> $326.12M</p>
<div class="lb-trans"><p><strong>市值：</strong> 3.2612 亿美元</p>
</div><p>Aclaris Therapeutics, with a market cap of US$326.12 million, is navigating the volatile penny stock landscape while focusing on immune-inflammatory treatments. Despite being unprofitable and facing increasing losses, the company remains debt-free and maintains a strong cash position with short-term assets of US$100.6 million exceeding liabilities. Recent inclusion in the NASDAQ Biotechnology Index may enhance visibility among investors. Revenue has declined to US$3.3 million for Q3 2025 from US$4.35 million a year ago, but revenue growth is projected at 22.29% annually, providing potential upside amidst high share price volatility and an inexperienced management team.</p>
<div class="lb-trans"><p>Aclaris Therapeutics 市值为 3.2612 亿美元，正在应对波动的便士股票市场，同时专注于免疫炎症治疗。尽管处于亏损状态且亏损不断增加，但公司无债务，保持强劲的现金状况，短期资产为 1.006 亿美元，超过负债。最近被纳入纳斯达克生物技术指数可能会提高投资者的关注度。收入从去年同期的 435 万美元下降至 2025 年第三季度的 330 万美元，但预计年收入增长率为 22.29%，在股价波动性较大和管理团队经验不足的情况下提供潜在的上行空间。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Aclaris Therapeutics' financial health report.</li>
<li>Gain insights into Aclaris Therapeutics' future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 Aclaris Therapeutics 财务健康报告中的详细发现。</li>
<li>通过查看我们的增长报告，获取 Aclaris Therapeutics 的未来方向的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b035627f-e16a-442f-99a6-969783c043a7/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/b035627f-e16a-442f-99a6-969783c043a7/chart/debt-equity-history-analysis"/></p>
<p>ACRS Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ACRS 债务与股本历史及分析</p>
</div><h2>Prelude Therapeutics (PRLD)</h2>
<div class="lb-trans"><h2>Prelude Therapeutics (PRLD)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Prelude Therapeutics Incorporated is a clinical-stage precision oncology company dedicated to discovering and developing novel cancer medicines for underserved patients, with a market cap of $242.25 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家临床阶段的精准肿瘤学公司，致力于为服务不足的患者发现和开发新型癌症药物，市值为 2.4225 亿美元。</p>
</div><p><strong>Operations:</strong> Prelude Therapeutics generates revenue from its Biotechnology (Startups) segment, totaling $10.5 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> Prelude Therapeutics 从其生物技术（初创公司）部门产生收入，总计 1050 万美元。</p>
</div><p><strong>Market Cap:</strong> $242.25M</p>
<div class="lb-trans"><p><strong>市值：</strong> 2.4225 亿美元</p>
</div><p>Prelude Therapeutics, with a market cap of US$242.25 million, is navigating the penny stock arena by focusing on precision oncology. Despite being unprofitable and having a negative return on equity, it has no debt and maintains sufficient short-term assets to cover liabilities. The company recently raised US$25 million through private placement and filed a shelf registration for US$9.125 million, indicating efforts to bolster its cash runway beyond the current 7 months. Recent preclinical data presentations at major conferences highlight promising developments in their JAK2V617F inhibitors and mCALR-targeted therapies, potentially enhancing investor interest despite high share price volatility.</p>
<div class="lb-trans"><p>Prelude Therapeutics 市值为 2.4225 亿美元，专注于精准肿瘤学，正在应对便士股票市场。尽管处于亏损状态且股本回报率为负，但公司无债务，保持足够的短期资产以覆盖负债。公司最近通过私募融资筹集了 2500 万美元，并申请了 912.5 万美元的货架注册，表明其努力在当前的 7 个月现金流之外增强现金储备。最近在主要会议上展示的临床前数据突显了其 JAK2V617F 抑制剂和 mCALR 靶向疗法的有希望进展，尽管股价波动性较大，但可能会增强投资者的兴趣。</p>
</div><ul>
<li>Navigate through the intricacies of Prelude Therapeutics with our comprehensive balance sheet health report here.</li>
<li>Review our growth performance report to gain insights into Prelude Therapeutics' future.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的综合资产负债表健康报告，深入了解 Prelude Therapeutics 的复杂性。</li>
<li>查看我们的增长表现报告，以获取对 Prelude Therapeutics 未来的洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis"/></p>
<p>PRLD Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月 PRLD 债务与股本历史及分析</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>将想法转化为行动</h2>
</div><ul>
<li>Take a closer look at our US Penny Stocks list of 339 companies by clicking here.</li>
<li>Contemplating Other Strategies? The latest GPUs need a type of rare earth metal called Terbium and there are only 38 companies in the world exploring or producing it. Find the list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里仔细查看我们 339 家美国便士股票公司的名单。</li>
<li>考虑其他策略？最新的 GPU 需要一种叫做铽的稀土金属，全球只有 38 家公司在探索或生产它。免费获取名单。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾难应对</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的，而是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

3 只市值低于 4 亿美元的有前景的便士股